Asahi Kasei company Zoll has signed an exclusive distribution agreement with BrainCool for the BrainCool System/IQool System and the IQool System Pads in the US and major European markets.
The companies also plan to work together to expand distribution to selected Asian markets.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The agreement broadens Zoll’s range of temperature management solutions, encompassing both intravascular technology and surface options.
Branded as the IQool System in the US, the BrainCool System is an advanced surface temperature management system with gel-free and adhesive-free pads.
This system is intended to maintain fever control and manage patient temperature in critical care settings.
The IQool System has programmable protocol settings and acute temperature control, as well as an advanced user interface.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataZoll Circulation president Christopher Barnabas said: “Expanding Zoll’s temperature management offering to include a high-quality surface option supports our mission to improve patient outcomes and help save lives.
“With our Thermogard XPand Thermogard HQ products – the world’s only intravascular temperature management technology – and BrainCool’s IQool System, we now offer a unique combination of solutions that deliver high-quality patient care while recognising hospitals’ evolving protocols and increased nursing workload.”
In May this year, Zoll secured approval from the US Food and Drug Administration for its remedē system for conditional use with magnetic resonance imaging.
The implantable transvenous phrenic nerve stimulator is intended for treating patients who experience moderate to severe central sleep apnea.
